Press release from Emotra AB (publ)

Göteborg, 7 February, 2022

EUDOR-A study data have been published

The data from our clinical multi-center study EUDOR-A have now been published. This study, which examined hyporeactivity in depressed patients and its connection to risk of suicide and suicide attempts, has been published in the scientific journal Frontiers in Psychiatry. The published study demonstrates that hyporeactive patients run a greater risk of suicide attempts compared with normally reactive patients.

Our article "A Naturalistic, European Multi-Center Clinical Study of Electrodermal Reactivity and Suicide Risk Among Patients With Depression" has now been published in the scientific journal Frontiers in Psychiatry.

In this study, 1,753 patients diagnosed with primary depression in their clinical assessment were tested with EDOR® and were followed up a year after the test. Both the physician and the patient were aware that they were participating in the study and the results were communicated to the doctors, who were encouraged to weigh in the test results in their risk assessments. The findings in our published article show that hyporeactive patients ran an increased risk of suicide attempts, both historically in connection with the clinical assessment and after follow-up. The number of suicides in the study population was 8, which is too small an amount to enable a statistical analysis.

Link to the article:Frontiers | A Naturalistic, EuropeanMulti-CenterClinical Study of Electrodermal Reactivity and Suicide Risk Among Patients With Depression | Psychiatry (frontiersin.org)

"Both we as a company and the many clinics that participated in the study have been waiting a long time for these findings to be published. These findings are in line with our disclosures in earlier press releases and semi-annual reports, and make an important contribution to our knowledge of hyporeactivity in depressed patients," Daniel Poté, Emotra's President, commented.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail:

daniel@emotra.se

__________________________________________________________________________________

Emotra AB (publ) is a medical technology company that carries out research, development, clinical

studies and marketing in the area of neurological research mental health. The Company's

methods/products, NeuraMetrix TC and EDOR®, are unique, proprietary and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden

Tel: +46 732-34 41 93, www.emotra.se

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Emotra AB published this content on 10 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 February 2022 18:02:04 UTC.